Key result
Warfarin withdrawal and enoxaparin treatment promptly resolved symptoms of purple toe syndrome in a 65-year-old female with Factor V Leiden mutation.
Case Report (n=1)
Enoxaparin can successfully treat purple toe syndrome, a rare complication of warfarin therapy, in patients requiring continued anticoagulation.
May support enoxaparin substitution in warfarin-induced purple toe syndrome; leaves open confirmation in prospective studies.
Purple toe syndrome is a rare complication of warfarin therapy. It occurs usually after 3 to 8 weeks of therapy and it is caused by cholesterol emboli from atheromatous plaque. Sudden onset of pain in affected area, typically in toes and feet, is the main characteristic of the syndrome. We describe a case of a 65-year-old female with purple toe syndrome after 6 weeks of warfarin. Indication of warfarin was a proximal deep venous thrombosis, which developed after prolonged immobilization. Factor V (FV) Leiden and persistent high FVIII activity were found as additional eliciting factors for venous thromboembolism. After warfarin withdrawal and enoxaparin treatment, symptoms disappeared promptly but a slight discoloration of the toe persists.
No takes yet. Share an insight, caveat, or question.
Ďulíček et al. (2012) conducted a case report in Purple toe syndrome (n=1). Enoxaparin and warfarin withdrawal was evaluated on Symptom resolution. Warfarin withdrawal and enoxaparin treatment promptly resolved symptoms of purple toe syndrome in a 65-year-old female with Factor V Leiden mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: